Drugs / UF-KURE-BCMA
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07611149 Comparator | Sep 2026 → Sep 2028 expected | plasma cell myeloma | Kure Cells, INC | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UF-KURE-BCMA | “The Investigational Product is UF-KURE-BCMA, an autologous CAR-T cells manufactured using an ultra-fast process” NCT07611149 ↗ |
| Modality | Cell therapy | “an autologous CAR-T cells” NCT07611149 ↗ |
| Route | Other | “CAR-T cell infusion” NCT07611149 ↗ |